--- title: "Relmada Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286158030.md" datetime: "2026-05-12T21:04:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286158030.md) - [en](https://longbridge.com/en/news/286158030.md) - [zh-HK](https://longbridge.com/zh-HK/news/286158030.md) --- # Relmada Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.22. EBIT: As of FY2026 Q1, the actual value is USD -20.42 M. #### Operational Metrics Relmada Therapeutics, Inc. reported a net loss of - $19.1 million for the three months ended March 31, 2026, compared to a net loss of - $17.6 million for the same period in 2025. Loss per basic and diluted share was - $0.22 for the first quarter of 2026, an improvement from - $0.58 in the first quarter of 2025. Research and development expenses for the three months ended March 31, 2026, totaled $8.1 million, a decrease of $3.9 million from $12.0 million in the prior year period. General and administrative expenses increased by approximately $5.1 million, totaling $11.4 million for the three months ended March 31, 2026, compared to $6.3 million for the same period in 2025. Total operating expenses for the three months ended March 31, 2026, were $19,461,754, up from $18,218,435 in the prior year period. Loss from operations was - $19,461,754 for Q1 2026, compared to - $18,218,435 for Q1 2025. #### Cash Flow Net cash used in operating activities for the three months ended March 31, 2026, was - $15.1 million, an improvement from - $18.1 million for the three months ended March 31, 2025. Net cash used in investing activities was - $135,226,997 for the three months ended March 31, 2026, compared to net cash provided by investing activities of $15,359,713 for the same period in 2025. Net cash provided by financing activities was $156,574,345 for the three months ended March 31, 2026, while there was no net cash from financing activities in the prior year period. Cash and cash equivalents at the end of the period were $9,776,400 as of March 31, 2026, compared to $1,149,706 as of March 31, 2025. #### Unique Metrics As of March 31, 2026, Relmada Therapeutics, Inc. had a balance of $234.0 million in cash, cash equivalents, and short-term investments, which includes net proceeds of approximately $150 million from a private placement financing announced on March 9, 2026, compared to approximately $93.0 million at December 31, 2025. Gross proceeds from the private placement were $160 million. As of May 7, 2026, the company had 104,890,223 shares outstanding. Common shares outstanding were approximately 104.9 million as of March 31, 2026, including approximately 15.0 million outstanding options with a weighted average exercise price of $12.51 per share and approximately 8.0 million outstanding warrants. In the NDV-01 Clinical Trial (TRCG-001) for High-Risk NMIBC, efficacy results for evaluable patients (n=38) showed a 95% anytime Complete Response (CR) rate and an 83% 12-month Kaplan-Meier CR rate. For the BCG-unresponsive subpopulation (n=17), efficacy results showed a 94% anytime CR rate and an 84% 12-month Kaplan-Meier CR rate. No patient experienced progression to muscle invasive disease or underwent a radical cystectomy, and no patient had a Grade 3 or higher treatment-related adverse event (TRAE) or discontinued treatment due to AEs. The 2L BCG-unresponsive NMIBC market is estimated to be approximately 5,000 patients annually in the U.S., while the intermediate-risk NMIBC market is estimated at approximately 75,000 patients annually in the U.S. The NDV-01 Phase 3 RESCUE Trial includes Cohort 2A (2L BCG-Unresponsive NMIBC) with a target enrollment of N=87, Cohort 1 (Adjuvant Intermediate-Risk NMIBC) with a target enrollment of N=276, and Cohort 2B (2L BCG-Unresponsive NMIBC, exploratory) with a target enrollment of N=30. #### Outlook / Guidance Relmada Therapeutics, Inc.’s current cash, cash equivalents, and short-term investments of $234.0 million as of March 31, 2026, are expected to fund operations through 2029, including the completion of the Phase 3 NDV-01 RESCUE program. The company is on track to initiate the Phase 3 RESCUE registrational program for NDV-01 and the Phase 2 study for Sepranolone in mid-2026, with initial 3-month NDV-01 data from the Phase 3 2L BCG-unresponsive study expected by year-end 2026. A provisional patent application for NDV-01, filed in April 2026, could lead to patents with a term until April 2047 if issued. ### Related Stocks - [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md) ## Related News & Research - [Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors](https://longbridge.com/en/news/271349213.md) - [Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/285098818.md) - [Factorial Files Super 8-K Containing Q1 2026 Financial Results | FAC Stock News](https://longbridge.com/en/news/289602927.md) - [How Investors Are Reacting To Cardinal Health (CAH) Raising Guidance While Expanding Theranostics Amid Recall](https://longbridge.com/en/news/288985099.md) - [Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors | ALDX Stock News](https://longbridge.com/en/news/289251268.md)